Epocal Receives FDA Clearance For Glucose Test

Epocal has received US Food and Drug Administration’s (FDA) clearance to market its new glucose test on the epoc Blood Analysis System.

Imants Lauks, president and founder of Epocal, said: The FDA clearance of glucose represents one of many milestones to come for Epocal and for healthcare as we continue to expand the test menu of the first wireless and cost effective point of care testing system. We are very excited to offer an award winning technology that enables hospitals worldwide to improve the delivery of patient care, reduce their operating expenses and operate more efficiently.

Epocal is implementing an entire blood diagnostic system in FlexCard technology, a card format similar to the smart card used in conventional cheque and telephone cards.